CodeLaunch, which pairs startups with software consultants, is returning to Houston this spring. Photo via codelaunch.com

A traveling seed-stage accelerator has announced its return to Houston and named its second cohort.

CodeLaunch, produced by Dallas-based constant and software development company Improving and presented by Ohio-based VC network Cyrannus, is returning to Houston. The company's second Houston accelerator event will be held on March 2.

Putting a fresh spin on the seed accelerator model, CodeLaunch combines a startup competition with a tech tradeshow, as well as allows for networking among attendees. Since its inception ten years ago, the touring competition has doled out over $1.4 million in services to its finalists and overall winners.

"CodeLaunch is a startup and rock-n-roll show like nothing you've ever seen before," says CodeLaunch President and Founder Jason W. Taylor in a news release.

The competition pairs six startups with six startup consulting companies. This year's finalists and mentor pairings are as follows:

  • Lake Charles, Louisiana-based GOPHR's consultant mentor is Softeq
  • Port Arthur, Texas-based DrinKicks is paired with BJSS
  • Energy360, based in Houston, has been matched with Honeycomb Software
  • Inpathy, based in Detroit and Tyler, Texas, will work with Contollo
  • Drivingo, led by a student founder from Virginia Tech, is selected to collaborate with Blue People
  • Houston-based AnyShift's consultant mentor is Improving

Houston-based Softeq is returning to the event after working with software startup Codiac.

“CodeLaunch was great. We gained customers, investors, and a lot of local notoriety. It was the best event we had all last year," says Ben Ghazi, founder of Codiac about the event.

ResQ TRX, a Houston startup that provides solutions for the logistics industry, won CodeLaunch HOU 2022. Houston-based Clutch won Judges' Choice in last year's competition.

This year, investment is also on the line. Presenting partner Cyrannus announced that all startup founders who advance to the semifinal round of CodeLaunch will be competing in a $100,000 investment challenge, as well as the $50,000 challenge for impact startups. There would be one or two winners — either a winner for each award or, if a company scores top marks in both categories, one company can take home the entire $150,000.

“Not only will (a winner) get the cash, but also be introduced to a network that will help them refine their idea and get ready for their first big fundraiser," says Lee Mosbacker, founder of Cyrannus, in a news release.

This year's CodeLaunch event will be a part of Houston Tech Rodeo, which is taking place February 27 to March 2 this year. Tech Rodeo, which announced its schedule this week, will conclude its programming with the CodeLaunch event.

"Houston Exponential could not be more excited about our partnership with CodeLaunch Houston," says Houston Exponential CEO Natara Branch in the release. "They are a fantastic ally in Houston’s efforts to serve its growing startup community and CodeLaunch is an incredible fit for the capstone of the 2022 Tech Rodeo. Finishing off Tech Rodeo with CodeLaunch's exciting atmosphere will be a highly anticipated event for the Houston innovation ecosystem after an engaging week of programming."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

7+ can't-miss Houston business and innovation events in June 2026

where to be

Editor's note: The FIFA World Cup comes to Houston this month, joined by major energy conferences and a lineup of fan-favorite, recurring events. Here’s what not to miss and how to register. Please note: this article may be updated to add more events.


June 1-4 — CLEANPOWER 2026 Conference and Exhibition

CLEANPOWER unites policymakers, experts, and corporate leaders to solve the challenges that none can solve alone. This must-attend, four-day conference is packed with cutting-edge discussions about wind, solar, storage, and transmission; dealmaking; networking; and fun.

This event begins June 1 at the George R. Brown Convention Center. Register here.

June 2 — Humans of Healthcare

Houston Methodist Center for Innovation will present its quarterly speaker series, Humans of Healthcare. The series will feature a panel of experts who will share about their career paths and discuss the nuances of the health care industry. This month's session will focus on today’s nursing landscape, the industry’s expectations of nurses and what career paths are possible in the field.

The event is Tuesday, June 2, from 5-6:30 p.m. at the Ion. Register here.

June 9 — Greentown Go Make Kickoff

Head to the Ion to celebrate the Greentown Go Make 2026 cohort. The open-innovation program with Shell Catalysts & Technologies and Technip Energies focuses on catalytic solutions for industrial decarbonization and the energy transition. Hear pitches from the founders and network with a select group of startups while enjoying food and drink.

This event is Tuesday, June 9, from 5:30-8 p.m. Register here.

June 9-10 — Texas Brain Economy Summit

The Center for Houston’s Future and UTMB are bringing the Texas Brain Economy Summit back to Houston this summer to continue to position the region as a global leader in brain health. Expect to hear from leaders of global institutions, including the World Economic Forum, U.S. Chamber of Commerce, McKinsey Health Institute, Global Brain Economy Initiative, Davos Alzheimer’s Collaborative, Business Collaborative for Brain Health (UsAgainstAlzheimer’s), Rice University, Memorial Hermann, MD Anderson and many others. Read InnovationMap's full preview of the event here.

This event begins Tuesday, June 9. Purchase tickets here.

June 10 — MIT Future of Healthcare Technology Forum

The MIT Club of South Texas will host an in-person forum to explore how innovation, government and policy are changing the healthcare industry. The event will feature MIT alumni and Houston healthcare leaders, including Dr. Tim Boone, dean of the Texas A&M School of Engineering Medicine; Cynthia Reinhart-King, chair of bioengineering at Rice University; Dr. Tony Lin, CEO and chairman emeritus of Kelsey-Seybold Clinic; and others.

This event is Wednesday, June 10, from 5:15-8:30 p.m. at the TAMU EnMed Building. Register here.

June 11 — Goals & Gigawatts: Houston Energy & Climate Week The Power of & Kickoff Party

Come watch the Mexico City FIFA opening match while celebrating energy and innovation at the Goals & Gigawatts Kickoff Party. The event will feature food, drinks, and a showcase on Houston Energy & Climate Week. Learn what to expect and how to get involved in HECW before closing the night with a DJ and karaoke.

This event is Thursday, June 11, from 1:30-6:30 p.m. Find more information here.

June 16-17 — Energy Projects Conference & Expo

The Energy Projects Conference & Expo (EPC Show) is the largest event in North America for professionals working at the heart of major energy projects. The essential event for engineering, construction, commissioning, operations and maintenance across multiple energy sectors brings together five leading conferences under one roof. Conference subjects span LNG exporting, hydrogen and ammonia, midstream, petrochem and refining, and sustainable aviation fuels.

This event begins June 16 at George R. Brown Convention Center. Register here.

June 25 – NASA Tech Talk

Every fourth Thursday of the month, NASA experts, including longtime engineer Montgomery Goforth, present on technology development challenges NASA’s Johnson Space Center and the larger aerospace community are facing, and how they can be leveraged by Houston’s innovation community. Stick around after for drinks and networking at Second Draught.

This event is Thursday, June 25, from 6-7 p.m. at the Ion. Register here.

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”